GeoVax Relocates Headquarters and Labs to Atlanta Area to Support Growth and Pipeline Advancement

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and multi-antigen vaccines against cancers and infectious diseases, announced relocations of its corporate headquarters and laboratory operations to new facilities in the Atlanta metropolitan area. The moves, scheduled for fourth quarter of 2025, will support GeoVax's continued growth, expanding pipeline, and preparation for product commercialization.

GeoVax's laboratory group is relocating to Science Square / Portal Innovations, located in midtown Atlanta. This state-of-the-art facility will provide the Company's R&D team with expanded access to modern laboratories and collaborative research environments designed to accelerate innovation and development activities. The Company's new corporate headquarters will be located at 1955 Lake Park Drive in Smyrna, Georgia, establishing a new hub for corporate operations and leadership activities.

David Dodd, Chairman and Chief Executive Officer of GeoVax, stated that these moves reflect a significant milestone in GeoVax's evolution. By placing members of the R&D team in one of the most dynamic bio-research ecosystems in the Southeast and expanding the administrative base, GeoVax is positioning for an accelerated next stage of growth. These facilities will support the company's broad and advancing pipeline, which includes the promising GEO-MVA program and multiple clinical trials in cancer therapy and infectious disease vaccines.

Eddie Lai, Director of Business Development at Atlanta Portal Innovations, expressed excitement about GeoVax joining Portal Atlanta at Science Square Labs. GeoVax brings a strong legacy of innovation rooted in the Southeast to the Portal Innovations ecosystem that includes 100+ innovative companies utilizing sites across the country. As an innovation engine, Portal Innovations supports scientific companies including life sciences and biotech in all stages of development in both R&D and administrative capabilities.

The relocations underscore GeoVax's trajectory as a company focused on long-term growth, scientific advancement, and future commercialization opportunities. As the Company builds momentum with a deepening pipeline and strategic partnerships, its enhanced infrastructure will provide a strong foundation to meet global healthcare needs. For more information about the current status of clinical trials and other updates, visit www.geovax.com.

GeoVax's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as a primary vaccine for immunocompromised patients, a booster vaccine in patients with chronic lymphocytic leukemia, and a more robust, durable COVID-19 booster among healthy patients who previously received mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers.

GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. The company holds worldwide rights for its technologies and products, supported by a strong IP portfolio. These strategic relocations position GeoVax to advance its pipeline more efficiently while strengthening ties to Georgia's growing biotechnology ecosystem.